Biotech entity

ISM4808

Product

Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Insilico Medicine, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention ISM4808, all published on March 6, 2026.

Last mentioned: Mar 6, 2026

Entity pulse

Recent coverage · ISM4808

1 story
6 avg impact
100% positive
0% negative

Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.

  • 100% positive

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about ISM4808

Every one of those 1 sits in a single category, clinical-trial. Of the tracked stories, 1 of 1 also mention Insilico Medicine, the most common co-covered peer. Each carries 3 original sources on average. We currently track 1 Biotech story that mention ISM4808, all published on March 6, 2026.

Stories tracked
1
Sources per story
3

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering ISM4808. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Phase I Initiation

    First human subject enrolled and dosed in the Phase I clinical trial.

  2. Out-Licensing Deal

    TaiGen Biopharmaceuticals acquires rights for clinical development and commercialization.

  3. Candidate Discovery

    Insilico Medicine identifies ISM4808 using generative AI models.

Stories mentioning ISM4808 1

Clinical Trials Positive

Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I

Insilico Medicine and TaiGen Biopharmaceuticals have achieved a major clinical milestone with the first human dosing of ISM4808, an AI-discovered small molecule for Chronic Kidney Disease (CKD) anemia. This Phase I trial marks a critical validation point for Insilico’s Pharma.AI platform and triggers a milestone payment from TaiGen.

3 sources

ISM4808 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.